During the open-label run-in period, patients underwent spironolactone titration, with a target to 50 mg/daily, and those with hyperkalemia started SZC. Patients with normokalemia (potassium 3.5-5 ...
USA: The REALIZE-K trial shows that a daily oral potassium binder can safely enable the use of mineralocorticoid receptor ...